Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/222028
Title: | Natural history, immunological and genetic characteristics of preclinical inflammatory bowel disease (EARLY): study protocol for a prospective cohort study |
Author: | Rodríguez Lago, Iago Marigorta, Urko M. Mateos Andrés, Beatriz Mañosa Círia, Míriam Márquez Mosquera, Lucía Menchén, Luis Rodríguez Moranta, Francisco Alonso Abreu, Inmaculada Aguas, Mariam Alonso Galán, Horacio Borràs, Pere Castro Senosiain, Beatriz Domènech, Eugeni Ferreiro Iglesias, Rocío Francisco, Ruth de García Alonso, Francisco Javier García Morales, Natalia García Bosch, Orlando Gargallo, Carla Gisbert, J. P. Iglesias, Eva Mesonero, Francisco Ortiz de Zárate Sagastagoitia, Jone Ramos, Laura Sainz Arnau, Empar Ladrón Abia, Pablo Suria, Carles Suárez Ferrer, Cristina Tejido, Coral Varela, Pilar Vicente, Raquel Zabana, Yamile Castany, Gisela Rodríguez Perera, Eva Gutiérrez Casbas, Ana Barreiro de Acosta, Manuel EARLY Study Group from GETECCU |
Keywords: | Malalties inflamatòries intestinals Immunologia clínica Marcadors bioquímics Inflammatory bowel diseases Clinical immunology Biochemical markers |
Issue Date: | 12-May-2025 |
Publisher: | SAGE Publications |
Abstract: | Background: The period prior to the diagnosis of inflammatory bowel disease (IBD), defined as the preclinical phase, has emerged as a potential target for disease modification strategies. Despite the relevance of an early diagnosis to the prognosis of the disease, only a limited number of patients are diagnosed during this window of opportunity. Objectives: To determine the risk of developing symptoms after an incidental diagnosis of IBD and to describe the clinical, genetic, and immunological characteristics of IBD during its preclinical phase. Design: This study protocol describes a prospective, multicenter cohort study in which incidental (i.e., asymptomatic) IBD within the colorectal cancer screening program will be characterized from a clinical and multi-omic perspective and compared with symptomatic patients and healthy non-IBD controls. Methods: Samples from blood, urine, stool, and intestinal endoscopic biopsies will be obtained at baseline. A second sample set will be obtained after 52 weeks from those who remain asymptomatic; samples will also be obtained in those with new-onset symptoms. Medical treatment will be prescribed in all patients following current guidelines. Follow-up visits will be performed every 6 months for 10 years, and all new-onset symptoms, changes in disease behavior, extraintestinal manifestations, IBD-related medical therapies, or surgeries will be recorded. Two control cohorts will be included: one including recently diagnosed symptomatic IBD patients (<3 months), and another with healthy non-IBD controls after a normal ileocolonoscopy, in whom samples will be obtained at baseline. Samples from patients and controls will undergo genetic, proteomic, transcriptomic, single-cell RNA sequencing, metabolomic, and microbiome analyses, and integration of data between the different omic perspectives will also be performed. The study has been approved by the Basque Country Ethics Committee (PI2021116). Conclusion: EARLY will generate a unique dataset addressing a previously unexplored area of IBD, with the final aim of describing the prognosis of patients from its earlier phases on the disease and integrating clinical and omic data into useful tools for the long-term prediction of disease outcomes. |
Note: | Reproducció del document publicat a: https://doi.org/10.1177/17562848251338647 |
It is part of: | Therapeutic Advances in Gastroenterology, 2025, vol. 18 |
URI: | https://hdl.handle.net/2445/222028 |
Related resource: | https://doi.org/10.1177/17562848251338647 |
ISSN: | 1756-2848 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
rodriguez-lago-et-al-2025-natural-history-immunological-and-genetic-characteristics-of-preclinical-inflammatory-bowel.pdf | 488.86 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License